Correction: Corrigendum: The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease (Mucosal Immunology (2011) 4(5) (574–583), (S1933021922014210), (10.1038/mi.2011.18));The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease

Mucosal Immunology

Volumn 4, Issue 5, 2011, Pages 574-583

  Di Sabatino, A ^a   Battista, N ^b   Biancheri, P ^c   Rapino, C ^b   Rovedatti, L ^a   Astarita, G ^d   Vanoli, A ^a   Dainese, E ^b   Guerci, M ^a   Piomelli, D ^d   Pender, S L F ^e   MacDonald, T T ^c   MacCarrone, M ^b,f   Corazza, G R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF TERAMO   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; GAMMA INTERFERON; METHANANDAMIDE; PALMIDROL; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPASE D; STAT4 PROTEIN; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIGESTIVE SYSTEM; DOWN REGULATION; ENTERITIS; ENZYME ACTIVITY; ENZYME SYNTHESIS; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTESTINE BIOPSY; LAMINA PROPRIA; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; MYOFIBROBLAST; ORGAN CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULCERATIVE COLITIS;

EID: 84860390304     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2011.23     Document Type: Erratum

References (47)

1. Bouma, G. & Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3, 521-533 (2003). (Pubitemid 37328672)
2. MacDonald, T. T & Monteleone, G. Immunity, inflammation, and allergy in the gut. Science 307, 1920-1925 (2005).
3. Gordon, J. N., Di Sabatino, A. & MacDonald, T. T. The pathophysiologic rationale for biological therapies in inflammatory bowel disease. Curr. Opin. Gastroenterol. 21, 431-437 (2005). (Pubitemid 40961169)
4. Kunos, G. & Pacher, P. Cannabinoids cool the intestine. Nat. Med. 10, 678-679 (2004) (Pubitemid 38937629)
5. Izzo, A. A. & Camilleri, M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 57, 1140-1155 (2008).
6. Storr, M. A. et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J. Mol. Med. 86, 925-936 (2008).
7. Muccioli, G. G. Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug. Discov. Today 15, 474-483 (2010).
8. Petrosino, S., Ligresti, A. & Di Marzo, V Endocannabinoid chemical biology: a tool for the development of novel therapies. Curr. Opin. Chem. Biol. 13, 309-320 (2009)
9. Pertwee, R. G. et al. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62, 588-631 (2010).
10. De Petrocellis, L & Di Marzo, V Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J. Neuroimmune. Pharmacol. 5, 103-121 (2010).
11. Solorzano, C. et al. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc. Natl. Acad. Sci. USA 106, 20966-20971 (2009).
12. Ueda, N., Tsuboi, K. & Uyama, T. Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim. Biophys. Acta. 1801, 1274-1285 (2010).
13. Petrosino, S. & Di Marzo, V FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr. Opin. Investig. Drugs 11, 51-62 (2010).
14. Fezza, F., De Simone, C, Amadio, D. & Maccarrone, M. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell. Biochem. 49, 101-132 (2008).
15. Izzo, A. A. & Sharkey K. A. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol. Ther. 126, 21-38 (2010).
16. Tanasescu, R. & Constantinescu, C. S. Cannabinoids and the immune system: an overview. Immunobiology 215, 588-597 (2010).
17. Cencioni, M. T et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 5, e8688 (2010).
18. Maccarrone, M. et al. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch. Biochem. Biophys. 393, 321-328 (2001)
19. Smid, S. D. Gastrointestinal endocannabinoid system: multifaceted roles in the healthy and inflamed intestine. Clin. Exp. Pharmacol. Physiol. 35, 1383-1387 (2008).
20. Massa, F. et al. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113, 1202-1209 (2004) (Pubitemid 38544105)
21. Marquéz, L. et al. Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One 4, e6893 (2009)
22. D Argenio, G. et al. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J. 20, 568-570 (2006)
23. Di Marzo, V. & Izzo, A. A. Endocannabinoid overactivity and intestinal inflammation. Gut 55, 1373-1376 (2006). (Pubitemid 44476773)
24. Klein, T. W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5, 400-411 (2005). (Pubitemid 40685989)
25. Lunn, C. A., Reich, E. P. & Bober, L. Targeting the CB2 receptor for immune modulation. Expert. Opin. Ther. Targets 10, 653-663 (2006) (Pubitemid 44479974)
26. Rieder, S. A., Chauhan, A., Singh, U., Nagarkatti, M. & Nagarkatti, P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 215, 598-605 (2010)
27. Börner, C, Höllt, V & Kraus, J. Activation of human T cells induces upregulation of cannabinoid receptor type 1 transcription. Neuroimmunomodulation 14, 281-286 (2007) (Pubitemid 351737854)
28. Wright, K. L., Duncan, M. & Sharkey, K. A. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J. Pharmacol. 153, 263-270 (2008).
29. Croxford, J. L & Yamamura, T. Cannabinoids and the immune system potential for the treatment of inflammatory diseases? J. Neuroimmunol. 166, 3-18 (2005). (Pubitemid 41074652)
30. Wacnik, P. W. et al. Cannabinoids affect dendritic cell (DC) potassium channel function and modulate DC T cell stimulatory capacity J. Immunol. 18, 3057-3066 (2008)
31. Rovedatti, L, Kudo, T. & Biancheri, P. et al. Differential regulation of interleukin-17 and interferon-γ production in inflammatory bowel disease. Gut 58, 1629-1636 (2009).
32. Engel, M. A. et al. Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide. J. Physiol. Pharmacol. 59, 673-689 (2008)
33. Thieu, V. T. et al. Signal transducer and activator of transcription 4 is required for the transcription factor T-bet to promote T helper 1 cell-fate determination. Immunity 29, 679-690 (2008).
34. Julien, B. et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128, 742-755 (2005) (Pubitemid 40585376)
35. Akhmetshina, A. et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 60, 1129-1136 (2009).
36. Burke, J. P. et al. Fibrogenesis in Crohn's disease. Am. J. Gastroenterol. 102, 438-448 (2007).
37. Powell, D. W. et al. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am. J. Physiol. 277, C183-C201 (1999). (Pubitemid 29415032)
38. Best, W. R. et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 70, 439-444 (1976).
39. Rachmilewitz, D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized study. BMJ 298, 82-86 (1989). (Pubitemid 19032930)
40. Francavilla, F. et al. Characterization of the endocannabinoid system in human spermatozoa and involvement of transient receptor potential vanilloid 1 receptor in their fertilizing ability. Endocrinology 150, 4692-4700 (2009).
41. Okamoto, Y et al. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279, 5298-5305 (2004). (Pubitemid 38220550)
42. Fezza, F. et al. Radiochromatographic assay of N-acyl-phosphatidyl- ethanolamine-specific phospholipase D activity Anal. Biochem. 339, 113-120 (2005) (Pubitemid 40342685)
43. Fegley, D. et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation J. Pharmacol. Exp. Ther. 313, 352-358 (2005). (Pubitemid 40411361)
44. 2+ channels inhibits Th1 cytokine production and T-box transcription factor T-bet in inflammatory bowel disease. J. Immunol. 183, 3454-3462 (2009).
45. Di Sabatino, A. et al. Functional modulation of Crohn's disease myofibroblasts by anti-TNF antibodies. Gastroenterology 133, 137-149 (2007). (Pubitemid 47031137)
46. Rodriguez, L. G., Wu, X. & Guan, J. L. Wound-healing assay. Methods Mol. Biol. 294, 23-99 (2005).
47. Di Sabatino, A. et al. Transforming growth factor-ß signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 58, 777-789 (2009)